AC IMMUNE SA SF-02 (IMR) — Strategic Asset Allocation Index
AC IMMUNE SA SF-02 (IMR) has a Strategic Asset Allocation Index of 1.7% as of June 2026. Strategic assets (PP&E of €- plus long-term investments of €585.00K) total €585.00K, measured against net assets of €35.17 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See IMR equity to assets ratio to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
AC IMMUNE SA SF-02 Strategic Asset Allocation Index (2021–2025)
This chart shows how AC IMMUNE SA SF-02's Strategic Asset Allocation Index has evolved across 5 annual periods from 2021 to 2025. As of June 2026, the index stands at 1.7%, representing strategic assets of €585.00K against net assets of €35.17 Million EUR. For live market cap and overall valuation, see IMR market cap.
Annual Strategic Asset Allocation Index for AC IMMUNE SA SF-02 (2021–2025)
The table below presents the year-by-year Strategic Asset Allocation Index for AC IMMUNE SA SF-02 from 2021 to 2025, covering 5 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See IMR net assets for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (EUR) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 1.3% | €584.00K | €- | €584.00K | €44.88 Million | ▲ +0.9 pp |
| 2024 | 0.4% | €415.00K | €- | €415.00K | €112.27 Million | ▲ +0.1 pp |
| 2023 | 0.2% | €361.00K | €- | €361.00K | €160.64 Million | ▲ +0.0 pp |
| 2022 | 0.2% | €361.00K | €- | €361.00K | €168.99 Million | ▲ +0.1 pp |
| 2021 | 0.2% | €363.00K | €- | €363.00K | €231.98 Million | — |